We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
ResMed
RMD
$30.3B
| $56.4M | 0.09% |
363,678
+20,142
| +6% | +$2.9M |
|
202
Xcel Energy
XEL
$48.8B
| $56M | 0.09% |
881,522
+12,251
| +1% | +$766K |
|
203
LyondellBasell Industries
LYB
$19.5B
| $55M | 0.09% |
582,511
-36
| -0% | -$3.3K |
|
204
Regeneron Pharmaceuticals
REGN
$76B
| $54.8M | 0.09% |
146,062
+4,581
| +3% | +$1.54M |
|
205
Hilton Worldwide
HLT
$72.5B
| $54.8M | 0.09% |
493,643
+12,092
| +3% | +$1.21M |
|
206
Public Service Enterprise Group
PEG
$38.6B
| $54.7M | 0.09% |
927,015
+41,068
| +5% | +$2.49M |
|
207
eBay
EBAY
$50.4B
| $54.6M | 0.09% |
1,512,910
-19,346
| -1% | -$701K |
|
208
SBA Communications
SBAC
$19.3B
| $54.2M | 0.09% |
224,868
+12,308
| +6% | +$2.92M |
|
209
Zimmer Biomet
ZBH
$18.4B
| $53.8M | 0.09% |
370,045
+11,813
| +3% | +$1.63M |
|
210
KLA
KLAC
$236B
| $53.7M | 0.09% |
3,014,890
+118,940
| +4% | +$2M |
|
211
Equity Residential
EQR
$25.2B
| $53.7M | 0.09% |
663,220
+37,825
| +6% | +$3.22M |
|
212
Mettler-Toledo International
MTD
$27.9B
| $53.1M | 0.09% |
66,880
-1,609
| -2% | -$1.16M |
|
|
INFO
213
DELISTED
IHS Markit Ltd. Common Shares
INFO
| $52M | 0.09% |
689,552
+19,674
| +3% | +$1.4M |
|
214
Consolidated Edison
ED
$40.4B
| $50.9M | 0.09% |
562,912
+33,112
| +6% | +$2.97M |
|
|
DFS
215
DELISTED
Discover Financial Services
DFS
| $50M | 0.08% |
589,538
+9,299
| +2% | +$767K |
|
216
Motorola Solutions
MSI
$71.5B
| $49.9M | 0.08% |
309,864
+17,231
| +6% | +$2.84M |
|
|
CERN
217
DELISTED
Cerner Corp
CERN
| $49.6M | 0.08% |
675,614
+16,556
| +3% | +$1.14M |
|
218
DTE Energy
DTE
$29.5B
| $49.4M | 0.08% |
446,919
+18,274
| +4% | +$1.97M |
|
|
PPL
219
PPL Corp
PPL
$26.8B
| $48.7M | 0.08% |
1,357,318
+48,488
| +4% | +$1.63M |
|
|
ALXN
220
DELISTED
Alexion Pharmaceuticals
ALXN
| $48.5M | 0.08% |
448,438
+3,075
| +0.7% | +$329K |
|
221
Archer Daniels Midland
ADM
$38.9B
| $48.5M | 0.08% |
1,045,717
-70,460
| -6% | -$3M |
|
222
Centene
CNC
$30.1B
| $48.2M | 0.08% |
766,867
+19,800
| +3% | +$1.07M |
|
|
XLNX
223
DELISTED
Xilinx Inc
XLNX
| $47.9M | 0.08% |
490,376
-45,736
| -9% | -$4.3M |
|
224
Edison International
EIX
$30.3B
| $47.7M | 0.08% |
632,439
+37,567
| +6% | +$2.66M |
|
225
TransDigm Group
TDG
$69.9B
| $47.4M | 0.08% |
84,566
+2,059
| +2% | +$1.13M |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.